DARVON-N W/ ASA
LOE Approachingaspirin; propoxyphene napsylate
NDAORALTABLET
Approved
Sep 1971
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DARVON-N W/ ASA is an oral tablet combining propoxyphene napsylate (an opioid analgesic) with aspirin for pain relief. This combination product targets mild-to-moderate pain management across multiple indications. The mechanism involves opioid receptor agonism (propoxyphene) paired with anti-inflammatory and analgesic activity (aspirin).
LOE Approaching
Moderate competitive pressure (30/100) signals a mature, crowded market with limited growth opportunity; brand teams are likely focused on retention and cost-management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Only 1 linked job opportunity reflects the product's mature, declining commercial stage. Career roles are minimal and likely focused on compliance, safety monitoring, or medical affairs support rather than growth-oriented positions.
DOCTORA
1 open roles linked to this drug
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.